Please ensure Javascript is enabled for purposes of website accessibility

3 Dividend Stocks I'd Buy Right Now

By Keith Speights - Apr 15, 2021 at 5:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Attractive dividend yields and solid businesses make these stocks stand out.

Recently, a young woman told me that her husband wanted to invest in dividend stocks. Both of them are in their twenties. My response to her was that at their age, they'd be better off focusing on stocks with solid long-term growth prospects, regardless of whether or not the stocks paid dividends. 

My reply would have been different if the couple had been in their sixties.

Investing in dividend stocks in order to secure steady income is a great idea. Of course, you still want solid underlying businesses behind the stocks. With the two criteria of steady income and solid businesses in mind, here are three dividend stocks I'd buy right now.

A roll of $100 bills next to a pad of sticky-notes with "dividends" written on the top note

Image source: Getty Images.

AbbVie

I think that AbbVie (ABBV 0.09%) ranks as one of the most attractive dividend stocks on the market right now. The big drugmaker's dividend yield currently tops 4.8%. AbbVie is only one dividend hike away from becoming a Dividend King -- S&P 500 members with at least 50 consecutive years of dividend increases.

A single product, Humira, generated over 40% of AbbVie's total revenue last year, but the autoimmune-disease drug loses U.S. patent exclusivity in 2023. Does this present a reason to worry about AbbVie's dividend? Nope.

The company has been preparing for a long time for the day when it could no longer depend so heavily on Humira. AbbVie now has several other drugs with strong growth potential, notably including the successors to Humira -- Rinvoq and Skyrizi.

AbbVie will definitely feel the sting as biosimilars take market share away from Humira. It expects total revenue will fall in 2023. However, the company predicts a return to modest growth in 2024, with robust growth throughout the rest of the decade. AbbVie's dividends should keep on flowing and growing.

Brookfield Renewable Partners

Brookfield Renewable Partners (BEP -1.25%) doesn't belong to dividend royalty as AbbVie does. However, the company has increased its distribution (what limited partnerships call dividends) by a 6% compound annual growth rate (CAGR) since 2000. Its distribution currently yields nearly 2.9%.

The company's underlying business model is as solid as they come. There hasn't been a better time for renewable energy.

Demand is rising as countries across the world seek to reduce carbon emissions. Brookfield Renewable stands out as a leader in the renewable energy industry with its hydroelectric, wind, solar, and storage facilities in North America, South America, Asia, and Europe.

I view the stock as a great pick for income-seeking investors. However, Brookfield Renewable is also a very good choice for growth-oriented investors. The company claims a 23 gigawatt development pipeline that's more than double its current 19 gigawatt installed capacity.

Brookfield Renewable's growth prospects aren't just for the next few years. CEO Connor Teskey said in the company's Q4 update that management "look[s] forward to a multi-decade opportunity to advance decarbonization and assist with the transition of global electricity grids to a more sustainable future." That's the kind of opportunity that any investor would like.

Enterprise Products Partners

If you really like high dividend yields, you'll want to check out Enterprise Products Partners (EPD -2.56%). Its distribution currently yields a mouthwatering 7.8%. The company has increased its distribution for 22 consecutive years with a CAGR of 7%.

The biggest knock against EPD is that it's a midstream player in the fossil fuel industry. Yes, there's a definite shift away from fossil fuels to renewable energy sources. However, EPD's business is built for the long term.

For one thing, overall energy consumption is expected to increase over the next few decades. The U.S. Energy Information Administration projects that the percentage of total energy consumption generated by natural gas will also increase. In addition, rising demand for plastics is driving increased use of petrochemicals. It's no accident that 93% of EPD's major capital projects under construction focus on petrochemicals, natural gas, and natural gas liquids.

My Motley Fool colleague Gregg Brewer recently included EPD among his three safest energy dividends right now. I think his take is correct. EPD probably isn't a stock that will appeal to growth investors, but if you're looking for a solid dividend stock, I think it's a keeper.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Enterprise Products Partners L.P. Stock Quote
Enterprise Products Partners L.P.
EPD
$24.00 (-2.56%) $0.63
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$153.93 (0.09%) $0.13
Brookfield Renewable Partners L.P. Stock Quote
Brookfield Renewable Partners L.P.
BEP
$34.76 (-1.25%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.